ArticleMolecular biology reports2026
Molecular dynamics simulations along with the synthesis of innovative engineered nanobodies targeting Interleukin-2.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterleukin-2 (IL-2) is an essential cytokine that plays a significant role in the immune response. The use of anti-IL-2 antibodies to inhibit IL-2 may help mitigate the excessive immune response observed in conditions such as lupus, rheumatoid arthritis, and multiple sclerosis. Single-domain VHH antibodies (nanobodies) offer advantages over traditional antibodies, including their small size, enhanced thermal stability, reduced immunogenicity, superior tissue penetration, and cost-effective production. Consequently, nanobodies have become a promising approach for the diagnosis and treatment of diseases. METHODS AND
resultsWe employed a structure-guided complementarity-determining region (CDR) grafting approach to design two anti-IL-2 nanobodies, denoted Nb-IL2-01 (derived from 7DR4) and Nb-IL2-02 (derived from 6YE3), by transplanting CDRs from established monoclonal antibodies into a nanobody framework. Molecular dynamics simulations were used to assess the predicted structural stability of the designed constructs and their potential molecular interactions with IL-2. Following expression in E. coli and purification, the capacity of the designed nanobodies to bind immobilized IL-2 was evaluated by enzyme-linked immunosorbent assay (ELISA). Molecular dynamics simulations predicted that the Nb-IL2-02/IL-2 complex would exhibit greater conformational stability than the Nb-IL2-01/IL-2 complex. Experimentally, both nanobodies demonstrated specific, concentration-dependent binding to IL-2 in ELISA, confirming that the designed constructs possess antigen-binding functionality.
conclusionsWe successfully generated IL-2-binding nanobody constructs using a CDR grafting-based design approach. The integration of computational design with experimental characterization demonstrates a feasible pipeline for developing functional single-domain binders against therapeutic targets. The specific binding of the designed nanobodies supports their potential as candidates for further development and optimization.
Indexed as
Identifiers
42053822What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.